In 173 patients with recurrent/metastatic nasopharyngeal carcinoma after ≥2 lines including PD-1/PD-L1 inhibitors, becotatug vedotin beat chemotherapy on response (30.2% vs 11.5%) and median PFS (5.82 vs 2.83 months; HR 0.63); interim OS not significant (HR 0.73).
RCTn = 173
Han et al. Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial